KIMMTRAK doubles the likelihood of being alive at five years for first line HLA-A*02:01+ patients with metastatic uveal melanoma
Immunocore Holdings plc announces that KIMMTRAK (tebentafusp-tebn) significantly improves five-year overall survival rates in first-line HLA-A*02:01 positive patients with metastatic uveal melanoma, doubling survival from 8% to 16%. The data, from the longest randomized Phase 3 trial in this disease and for any T cell engager in solid tumors, showc…